Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;6(6):328-38.
doi: 10.1177/2040622315608647.

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Francesco Caso  1 , Luisa Costa  1 , Antonio Del Puente  2 , Matteo Nicola Dario Di Minno  3 , Gelsy Lupoli  4 , Raffaele Scarpa  2 , Rosario Peluso  5
Affiliations
Review

Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies

Francesco Caso et al. Ther Adv Chronic Dis. 2015 Nov.

Abstract

Spondyloarthritis represents a heterogeneous group of articular inflammatory diseases that share common genetic, clinical and radiological features. The therapy target of spondyloarthritis relies mainly in improving patients' quality of life, controlling articular inflammation, preventing the structural joints damage and preserving the functional abilities, autonomy and social participation of patients. Among these, traditional disease-modifying antirheumatic drugs have been demonstrated to be effective in the management of peripheral arthritis; moreover, in the last decade, biological therapies have improved the approach to spondyloarthritis. In patients with axial spondyloarthritis, tumor necrosis factor α inhibitors are currently the only effective therapy in patients for whom conventional therapy with nonsteroidal anti-inflammatory drugs has failed. The aim of this review is to summarize the current experience and evidence about the pharmacological approach in spondyloarthritis patients.

Keywords: biological therapies; nonsteroidal anti-inflammatory drugs; spondyloarthritis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors do not have any conflicts of interest related to the subject matter.

References

    1. Abisror N., Mekinian A., Lavigne C., Vandenhende M., Soussan M., Fain O., et al. (2013) Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 12: 1143–1149. - PubMed
    1. Acosta Felquer M., Coates L., Soriano E., Ranza R., Espinoza L., Helliwell P., et al. (2014) Drug therapies for peripheral joint disease in psoriatic arthritis: a systematic review. J Rheumatol 41: 2277–2285. - PubMed
    1. Ash Z., Gaujoux-Viala C., Gossec L., Hensor E., FitzGerald O., Winthrop K., et al. (2012) A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and metaanalysis informing the EULAR recommendations for the management of psoriatic arthritis. Ann Rheum Dis 71: 319–326. - PubMed
    1. Atteno M., Costa L., Matarese A., Caso F., Del Puente A., Cantarini L., et al. (2014) The use of TNF-α blockers in psoriatic arthritis patients with latent tuberculosis infection. Clin Rheumatol 33: 543–547. - PMC - PubMed
    1. Atteno M., Peluso R., Costa L., Padula S., Iervolino S., Caso F., et al. (2010) Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. Clin Rheumatol 29: 399–403. - PubMed

LinkOut - more resources